Reply To: Traders Market Weekly: Balancing Expectations, Earnings and Money Flow

#62089
MoneyNeverSleeps
Participant

Acadia Pharmaceuticals (ACAD) Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome.

ACAD up 28.6%